Pharmaceuticals · Nasdaq

VTRSViatris Inc

Last close
$20.82 +0.7%
52-week range
$10.15 to $21.20
Market cap
$23.9B
Next earnings
Not scheduled

Fiscal 2025 at a glance

Revenue
$14.3B
-3% vs FY24
Net income
-$3.51B
-454% vs FY24
Free cash flow
$1.94B
-2% vs FY24
Net cash
-$13.1B
Cash $1.36B, debt $14.4B

Stock price

+34% since Nov 2020

Valuation vs its own history since 2020

Above its median since 2020 on all 3 multiples

Where each multiple sits today inside its own range since 2020, measured at every quarter end. The thin tick is the median.

P/E, trailing
n/a
n/a: No earnings
Median 9.7x, range 6.1x to 227x
Price / sales
1.6x
0.6x4.5x
91st percentile, above its median of 0.8x
EV / EBITDA
12.6x
6.4x196x
81st percentile, above its median of 9.6x
Price / free cash flow
11.3x
3.6x22.9x
96th percentile, above its median of 6.3x

Key statistics

Trailing 12 months unless noted, through the quarter ending 2026-09-30. Every figure carries its unit.

Valuation

P/E
n/aNo earnings
Earnings yield
n/aNot reported
Price / sales
1.6x
Price / book
1.7x
Price / operating cash flow
9.6x
EV / EBITDA
12.6x
EV / sales
2.4x
Free cash flow yield
8.8%

Profitability

Gross margin
35.4%
Operating margin
-0.03%
Net margin
-4.1%
Return on equity
-4.4%
Return on capital
-0.01%

Growth per year

Revenue, 3 years
-4.2%
Revenue, 5 years
+3.8%
Revenue, 7 years
+3.4%
EPS, 3 years
n/aNot meaningful (a loss in the window)

Balance sheet

Cash and investments
$1.79B
Total debt
$13.3B
Net cash
-$11.5B
Debt / equity
0.97x
Current ratio
1.55x

Shares and dividend

Shares outstanding
1.15B
Share count, 5 years
+134%
Beta, 1 year
0.64
Dividend yield
2.3%
Dividend per share, TTM
$0.48
Payout ratio
n/aNot meaningful

Every year we have of the business

Last 29 quarters, fiscal 2018 to 2025 and after. Hover a bar for its quarter.

Revenue and net incomeLatest quarter $3.73B
RevenueNet income
Gross profitLatest quarter $1.44B
EBITDALatest quarter $959M
Margins39 / 7 / -9%
GrossOperatingNet
Earnings per shareLatest quarter -$0.28
Cash flowLatest quarter $899M
OperatingCapexFree
Cash vs debtLatest quarter $1.79B
Cash and investmentsTotal debt
P/E historyNow n/a
P/E, median 9.7x dashed
P/S historyNow 1.6x
P/S, median 0.8x dashed

Where the revenue comes from

Brands went from 61% to 64% of revenue in 3 years

Share of revenue by product line, fiscal 2022 to 2025, as reported in the 10-K.

BrandsLipitorNorvascLyricaEpi Pen Auto InjectorsViagraOther
FY22
61%
$16.3B
FY23
64%
$15.4B
FY24
62%
$14.7B
FY25
64%11%10%
$14.3B
Fiscal 2025 by product line
Product lineRevenueSharevs FY24
Brands$9.18B64.2%-0%
Lipitor$1.55B10.8%n/a
Norvasc$710M5.0%n/a
Lyrica$487M3.4%n/a
Epi Pen Auto Injectors$470M3.3%n/a
Viagra$408M2.9%n/a
Other$1.42B9.9%n/a

Pharmaceuticals peers

The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.

CompanyMarket capRevenue growth Operating marginP/EP/SP/E vs own history
LLY ELI LILLY & Co $1.36T +46% n/a46.8x15.7x 60th percentile
JNJ Johnson & Johnson $688B +8% n/a43.4x6.9x 90th percentile
MRK Merck & Co., Inc. $364B +5% n/a152x5.4x 98th percentile
PFE Pfizer Inc $165B +1% n/a41.2x2.6x 97th percentile
BMY Bristol Myers Squibb Co $130B +4% n/a14.1x2.6x 13th percentile
VTRS Viatris Inc $23.9B +4% -0.03%No earnings1.6x No earnings

The company

Sector
Health Care
Industry
Pharmaceuticals
CEO
Scott A. Smith
Founded
2020
Headquarters
Canonsburg, PA
Fiscal year ends
December
Website
viatris.com/en

What it does

Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.

Description from Wikipedia (CC BY-SA).

Around the numbers

What the rest of EdgeStacker knows about VTRS.

Next report

No confirmed report date in the next 95 days yet.

Open the Earnings Hub
Big funds, latest 13F

Held by 728 active funds. Crowd level: quiet.

Open the Smart money tab